<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; expected</title>
	<atom:link href="http://www.tapanray.in/tag/expected/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Abbott – Piramal deal: the way future is expected to shape up</title>
		<link>http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=abbott-piramal-deal-the-way-future-is-expected-to-shape-up</link>
		<comments>http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/#comments</comments>
		<pubDate>Mon, 31 May 2010 01:30:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[expected]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[monopoly]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[valuation]]></category>
		<category><![CDATA[way]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=421</guid>
		<description><![CDATA[In my view, these are still very early days for such acquisitions of large domestic Indian pharmaceutical companies by the Global Pharma majors to gain momentum in the country. However, there is no doubt that in the near future, we &#8230; <a href="http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Emerging markets and a robust oncology portfolio expected to be the future growth engine of the global pharmaceutical industry&#8230; but not without associated pricing pressures.</title>
		<link>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures</link>
		<comments>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/#comments</comments>
		<pubDate>Thu, 08 Oct 2009 01:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[associated]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[engine]]></category>
		<category><![CDATA[expected]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[portfolio]]></category>
		<category><![CDATA[pressures]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[without]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=760</guid>
		<description><![CDATA[When the growth rate of the developed markets of the global pharmaceutical industry started slowing down along with the declining R&#38;D productivity, the emerging markets were identified as the new ‘El-Dorado’ by the global players. At the same time, new &#8230; <a href="http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
